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Purpose: To develop a core/shell nanodimer of gold (core) and silver iodine (shell) as a dual-modal
contrast-enhancing agent for biomarker targeted x-ray computed tomography (CT) and photoacoustic
imaging (PAI) applications.
Methods: The gold and silver iodine core/shell nanodimer (Au/AgICSD) was prepared by fusing
together components of gold, silver, and iodine. The physicochemical properties of Au/AgICSD
were then characterized using different optical and imaging techniques (e.g., HR- transmission
electron microscope, scanning transmission electron microscope, x-ray photoelectron spectroscopy,
energy-dispersive x-ray spectroscopy, Z-potential, and UV-vis). The CT and PAI contrast-enhancing
effects were tested and then compared with a clinically used CT contrast agent and Au nanoparticles.
To confer biocompatibility and the capability for efficient biomarker targeting, the surface of the
Au/AgICSD nanodimer was modified with the amphiphilic diblock polymer and then functionalized
with transferrin for targeting transferrin receptor that is overexpressed in various cancer cells.
Cytotoxicity of the prepared Au/AgICSD nanodimer was also tested with both normal and cancer
cell lines.
Results: The characterizations of prepared Au/AgI core/shell nanostructure confirmed the formation
of Au/AgICSD nanodimers. Au/AgICSD nanodimer is stable in physiological conditions for in vivo
applications. Au/AgICSD nanodimer exhibited higher contrast enhancement in both CT and PAI for
dual-modality imaging. Moreover, transferrin functionalized Au/AgICSD nanodimer showed specific
binding to the tumor cells that have a high level of expression of the transferrin receptor.
Conclusions: The developed Au/AgICSD nanodimer can be used as a potential biomarker targeted
dual-modal contrast agent for both or combined CT and PAI molecular imaging. C 2016 American
Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4939062]
Key words: contrast agent, core–shell, computer tomography, gold, silver iodine, nanoparticles,
photoacoustic imaging
1. INTRODUCTION
Diagnostic imaging and imaging assisted interventions play
important roles in clinical care and in the research and devel-
opment of precision medicine, a customized form of health-
care designed to address specific patient concerns. Currently,
various imaging modalities, such as x-ray computed tomog-
raphy (CT), magnetic resonance imaging (MRI), position
emission tomography (PET), and single photon emission
computed tomography (SPECT), are already available in
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clinical practices.1 Each of these imaging modalities offers
specific capabilities and functions with their strengths and
limitations related to the contrast mechanism associated to
the specific tissue and physiological conditions, sensitivity
and specificity to a disease specific measurement, the spatial
and anatomic coverage of organs, and the cost effectiveness
when applied to a specific diagnosis. To take advantage of
synergies while also reconciling the various limitations of each
individual modality, multimodal imaging approaches and sys-
tems are of great interest for preclinical research and clinical
practices. By integrating multiple imaging techniques with
compatible and complementary contrast agents, multimodal
imaging may offer several benefits, such as providing comple-
mentary diagnostic information given by the strengths of each
modality, reducing image acquisition and processing time, and
lowering the exposure risk with a one-time administration of
the multimodal and multifunctional contrast agent.2–4 There-
fore, there is an emerging need in developing novel multimodal
and multifunctional contrast materials and molecular imaging
probes for multimodal imaging applications. To date, a number
of integrated imaging modalities have been developed, includ-
ing MRI/optical,5 MRI/PET,6 PET/near-infrared (NIR) optical
fluorescence7,8 CT/MRI,9 CT/photoacoustic imaging (PAI),10
and SPECT/CT.11,12
Nanomaterials are particularly suited for developing novel
dual-modal imaging contrast agents, either with single compo-
sition13–16 or with hybrid of multiple components.17–20 The
latter has been shown for the enhanced properties for imag-
ing and therapeutics. Specifically, new nanoparticle based
contrast agents combining CT and PAI capabilities provide
fine anatomic details with CT and physiological or targeted
imaging with PAI for accurate detection and localization of
pathological lesions.21–23 For instance, Tian et al.22 recently
reported that Rb-TB can be employed as a new dual-modal
contrast agent for CT and PAI imaging because of its high
NIR optical absorption capability and strong x-ray attenua-
tion ability. Another study using Bi2S3@SiO2 nanorods as a
CT and PAT dual-modal contrast agent demonstrated a real-
time noninvasive visualization of nanorods distribution in the
gastrointestinal tract.23
Therefore, dual-modal contrast agents with well-controlled
structural, physical characteristics (i.e., size, and shell thick-
ness, shape, optical, thermal, MR relaxivities, and acoustic)
and high stability and functions in the physiological condi-
tions are highly desired, since, these agents lead to a better
understanding of real-time biological processes in a variety
of physiological or pathological conditions. Herein, we report
the development of a new class of CT-PAI dual-modal contrast
agents that are composed by a core/shell nanodimer of fused
gold and silver iodine (Au/AgICSD) coated with amphiphilic
PEG-b-AGE polymer and functionalized with CALNN pep-
tides that can be used for conjugating biomarker targeting
moieties. The developed Au/AgICSD nanodimer shows effi-
cient contrast enhancement in both CT and PAI and capability
of targeted imaging of cancer cells with transferrin receptor
(TfR) overexpression, demonstrating the potential to facilitate
targeted diagnosis and therapy with integrated CT and PAI
techniques.
2. MATERIALS AND METHODS
2.A. Materials
Hydrogen tetrachloroaurate() trihydrate (HAuCl4·3H2O),
trisodium citrate (HOC(COONa) (CH2COONa)2·2H2O) silver
nitrate (AgNO3), ascorbic acid (C6H8O6), CTAC((C16H33)
N(CH3)3Cl), and sodium iodide (NaI) were purchased from
Fisher chemicals. CALNN anchoring group was ordered from
California Peptide (San Diego, CA, USA). Transferrin, di-
methylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT),
the PD-10 desalting columns, and the FluoroTag™ FITC
conjugation kit were purchased from Sigma-Aldrich. All cell
culture materials (media and supplements) were purchased
from Invitrogen (Burlington, OH). The Omnipaque™ 350 was
purchased from Medline (Waukegan, IL). All chemicals were
used without further purification.
2.B. Methods
2.B.1. Preparation of the colloidal gold
nanoparticles (AuNPs)
Briefly, 0.03 g of HAuCl4 ·3H2O was dissolved in 300 ml
of water and heated to near boiling temperature. Aqueous
trisodium citrate solution (9 ml, 0.034 M, ca. 60 ◦C) was
added into the solution. The mixture was refluxed for 40 min
and then allowed to cool to room temperature. The result-
ing ruby red solution was stirred overnight and then finally
filtered (0.45 µm, Millipore filter) to collect AuNPs. Obtained
AuNPs were characterized by UV-vis spectroscopy, giving
the typical plasmon band at 520 nm. The as-prepared AuNPs
were concentrated by centrifugation and used as seeds for the
ensuing reaction for making the designed core–shell nanocom-
posites.
2.B.2. Preparation of the Au/AgICSD
The synthesized AuNPs were used as seeds while a mixture
of AgNO3 (2 mM) and KI (2 mM) was used as the precursor
for growing nuclei. The nucleation and growth kinetics of
the shells were manipulated. Briefly, an aqueous solution of
ascorbic acid (2 ml, 2 mM) was added into the solution with
AuNP seeds (5 ml, 185 nM). The resulted mixture was gently
stirred and heated to 60 ◦C for 15 min. Silver nitrate (4 ml,
2 mM) and KI (4 ml, 2 mM) were then added drop-wise into
the reaction mixture at a rate flow of 0.75 ml/min. The resulting
Au/AgICSD (a core diameter of 15 nm and a 4 nm thick
shell) was subjected to centrifugation (9000 rpm for 40 min)
to remove excess reagents and redispersed in 50 ml water. An
aqueous solution of citrate (5 ml, 100 mM) was added into
redispersed Au/AgICSD nanodimers and mixed overnight.
2.B.3. Preparation of PEG-b-AGE coated Au/AgICSD
In order to apply a coating layer on Au/AgICSD nano-
dimers for surface stabilization and functionalization, the ob-
tained core/shell nanodimers were transferred to THF solution
using thiolated styrene. Then, the polyethylene glycol and
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polyallyl glycidyl ether blocked co-copolymer (PEG-b-AGE),
synthesized as we previously reported, was applied to replace
the hydrophobic styrene molecules from the Au/AgICSD sur-
face. Briefly, Au/AgICSD nanodimers (10 mg) were dispersed
in THF (2 ml) and added drop-wise to the PEG-b-AGE solu-
tion in THF (18 ml, 5 mg/ml), stirred for 24 h at room temper-
ature. The resulted mixture was then added drop-wise to 200
ml DI water. This aqueous mixture was dialyzed against water
for 48 h to remove the excess THF and the unreacted polymer,
and then was further centrifuged at 3000 rpm for 5 min. The
resulted supernatant of AgI/AuCSD nanodimers was coated
by PEG-b-AGE grafted with –NH2 groups available for further
conjugation of selected targeting ligands.
2.B.4. Preparation of TfR targeted Au/AgICSD
(Tf-Au/AgICSD)
The PEG-b-AGE coated Au/AgICSD nanodimers were dis-
solved in PBS at the final concentration of 2 mg/ml and then
were incubated with a CALNN peptide linker at molar ratio of
1:4000 for 1 h. The resulting solution was purified on a PD-
10 column and CALNN conjugated Au/AgICSD nanodimers
were obtained. On the other hand, Tf was mixed with Traut’s
reagent (in the molar ratio of 1:15) in 0.1M borate buffer, pH
8.5, and incubated overnight at room temperature. The solu-
tion mixture was then purified with a desalting spin column
to remove the excess of Traut’s reagent and obtain the pure
thiolated transferrin moieties (Tf-SH). In the final step, the
CALNN functionalized Au/AgICSD nanodimers and Tf-SH
were incubated at room temperature for 4 h. Tf-Au/AgICSD
nanodimers were separated from the solution using a PD-10
desalting column. The process was repeated three times and
was performed at 4 ◦C. The estimation of transferrin moieties
conjugated on the surface of Au/AgICSD nanodimers was
determined using a BCA protein assay and the concentration
of gold was determined by spectroscopy methods. The molar
extinction coefficient used to determine their concentration
was ε = 3.67×108. It should be noted that in all the experiments
Tf molecules used were also labeled with fluorescent dye FITC
based on the vender (Sigma-Aldrich) provided protocol.
2.B.5. Electron microscope and spectroscopic
characterizations of Au/AgICSD
Both the size and morphology of the synthesized nan-
odimers were assessed using a transmission electron micro-
scope (TEM, HitachiH-7500 accelerating voltage 75 kV)
energy-dispersive x-ray spectroscopy (EDX). Scanning trans-
mission electron microscope (STEM) measurements were
performed with a FEI Tecnai G2 F30 super-twin transmission
electron microscope operating at 300 kV. The samples were
prepared by dropping a diluted amount of nanoparticles onto
the carbon coated grid to air-dry. The UV-vis absorption
spectra were obtained using a Shimadzu UV-2401PC UV-
visible spectrophotometer with a slit width of 1.0 nm. The
elemental composition of the synthesized nanoparticles was
assessed by using x-ray photoelectron spectroscopy (XPS)
with argon-ion etching. The qualitative and quantitative
analyses of the nanodimers were performed using a SPECS
custom-built system. Excitation was produced using the
aluminum anode of the x-ray source (hν = 1486.6 eV).
In addition, the surface charge and the hydrodynamic size
were measured by using a dynamic light scattering (DLS)
instrument (Malvern Zeta Sizer Nano S-90) equipped with a
22 mW He–Ne laser operating at 632.8 nm.
Inductively coupled plasma mass spectroscopy (ICP-MS)
was employed to quantitatively measure the composition of
each element of the Au/AgICSD core–shell nanodimers. The
ICP-MS measurements were carried out with a quadrupole
ICP-MS instrument (Elan DRC-e, PerkinElmer, Germany),
equipped with a cross flow nebulizer and a Scott double
pass spray chamber. Indium is used as an internal standard.
Before analysis of the torch position, RF power, nebulizer gas
flow, and lens voltage are carefully optimized. Standard Au
nanoparticles (AuNPs) were used as a reference material for
all analyses.
Statistical analyses for mean value, standard deviation, and
Student’s t-test of the measurements were performed using
Microsoft Office Excel software (Microsoft Corporation,
Redmond, WA, USA).
2.B.6. Cytotoxicity evaluation
Cytotoxicity of the nanoparticles was examined using
3-(4,5-dimethylthiazol-2-yl)-2,5-iphenyltetrazolium bromide
(MTT) assay with four different cell lines, i.e., HEK293 human
embryonic kidney cell, HeLa human cervical carcinoma
cell, MDA-MB-231 human breast cancer cell, and D556
human brain tumor medulloblastoma cell. The cells were
maintained as an adherent culture and grown as a monolayer
in a humidified incubator (95% air, 5% CO2) at 37 ◦C in a
cell culture flask containing medium supplemented with 1%
penicillin-streptomycin and 10% FBS. Cells were detached
and seeded in 96-well flat-bottom microplates at 4000 cells per
well. After 24 h recovery at 37 ◦C, the medium was replaced
with 100 µl medium containing nanoparticles (Au/AgICSD or
AuNPs) at various gold concentrations (12.5–400 µg/ml). For
the control cell sample, a fresh medium without nanoparticles
was added. After 24 h of incubation at 37 ◦C, 10 µl of MTT
solution (5 mg/ml) was added into each well following a
4 h incubation period. After removing the culture media,
the precipitated formazan was then dissolved in 10% SDS in
0.01M HCl. Finally, a microplate reader (Biotech Synergy2)
was used to measure the absorption of all samples (n= 6 per
group) at 570 nm. Cell viability was determined by comparing
the absorptions of cells incubated with and those without
nanoparticles.
2.B.7. Targeting and specific cell binding
of Au/AgICSD to cells with TfR over expression
D556 medulloblastoma cell lines with a high level of TfR
overexpression were used for testing the specificity of Tf-
Au/AgICSD. Cells treated with Tf-Au/AgICSD were labeled
with FITC at 37 ◦C for 3 h. Au/AgICSD conjugated with BSA
(BSA-Au/AgICSD) was prepared as a control for nontargeted
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agent. Briefly, cells were maintained as an adherent culture
and grown as a monolayer in a humidified incubator (95%
air, 5% CO2) at 37 ◦C in a cell culture dish containing medium
supplemented with 1% penicillin-streptomycin and 10% FBS.
Cells were then seeded in eight-well chambered slides at
the concentration of 50 000 cells per well. After 36 h of
incubation, the media were replaced and the nanoparticles
were added into the cell media at a final concentration of
5 nM and further incubated at 37 ◦C for 3 h. The cell media
were then discharged and the cells were washed three times
with PBS. The cell internalization of the targeted nanoparticles
was observed using a Zeiss (Germany) fluorescent microscope
with an excitation at wavelength 488 nm and emission at
wavelength 515 nm.
2.B.8. Evaluation of the contrast effect for computed
tomography imaging
Solutions of Au/AgICSD with gold concentrations varying
from 0.5× 103, 2.5× 103, 12.6× 103, 17.7× 103, 25× 103,
and 50× 103 nM were added into PCR tubes as imaging
phantoms for the investigating contrast-enhancing effect.
The contrast phantoms with distilled water as background
were scanned at a peak voltage of 45 keV using a micro-
CT consisting of a microfocus (12 µm) x-ray tube and a
flat panel x-ray detector at 48× 48 µm2 detector cell size.
AuNPs at similar Au concentrations with Au/AgICSD and
a clinically used iodine contrast agent, Omnipaque 350, at
different iodine concentrations of 4.2×103 and 9.7×103 nM
are included as controls. After a 4×4 binning in projection
data, tomographic images of the samples were reconstructed
at 0.192×0.192 mm2 pixel size, corresponding to a spatial
resolution of 2.6 lp/mm. Hounsfield unit (HU) values of each
sample were measured and compared. The CT contrast (i.e.,
CT number in HU) of each Au/AgICSD solution, is defined as
Contrast = MeanTarget−MeanBackground, where MeanTarget and
MeanBackground are the average CT numbers gauged in the
region of interest (ROI) placed in the target and background
(water) areas, respectively.
2.B.9. Measurement of photoacoustic (PA) signals
To test the capability of prepared nanocomposites for PAI,
we measured the photoacoustic signals of each sample using a
home-built PAI instrument. A Q-switched Nd:YAG laser was
adopted to provide 532-nm laser pulses with a full-width half-
maximum (FWHM) value of 6.5 ns. An OPO system (Vibrant
B, Opotek) pumped by the second harmonic of a Nd:YAG
laser (Brilliant B, Bigsky) was used to provide laser pulses
with a repetition rate of 10 Hz and a pulse width of 5.5 ns. The
wavelength for PA measurement in this study was 532 nm,
which was determined as an optical absorption wavelength
for both Au/AgICSD nanodimers and AuNPs according to
results from UV spectra of those nanoparticles. During the
PA measurement, each sample was placed in a glass tube
(2 mm in diameter) to avoid the variations that may be induced
by the illumination of strong laser on the sample, e.g., laser
induced temperature rise or change in optical absorption.
The laser beam, 2 mm in diameter, illuminates the sample
surface and generates PA signals which can be collected
by a 10 MHz focused transducer (V312, Panametrics). The
sample and the transducer were immersed in water for acoustic
coupling. The PA signals from the samples were recorded by
a digital oscilloscope (TDS 540B, Tektronics). To compare
the performance of Au/AgICSD and AuNPs, PA signals from
Au/AgICSD and AuNPs samples at different concentrations
were measured at intervals of 20, 10, and 7 nM, and at an
interval concentration that provided for a signal-to-noise ratio
(SNR) of 2.
3. RESULTS
3.A. Synthesis and characterization of Au/AgICSD
The schematic illustration of the major steps used for the
production of Au/AgICSD nanodimer is shown in Fig. 1.
Highly monodispersed citrate coated AuNPs with an averaged
core diameter of 15 nm were first synthesized and then
utilized as seeds for the growth of the shells. In order to
initiate the nucleation of shells, ascorbic acid was used as a
reduction agent and the iodine and silver shells were reduced
on the seed surface. The resulted core–shell nanodimers were
further decorated with PEG-b-AGE and CALNN anchoring
peptide.
To confirm and demonstrate the formation of the core/shell
structure along with the composition of the nanodimers, shell
coverage, and their surface protection, spectroscopic and elect-
ron microscopic imaging characterizations of Au/AgICSD
were performed using TEM, STEM, XPS, and ICP-MS.
TEM images [Figs. 2(A) and 2(C)] show the high and bright
contrast of the Au core compared with the AgI shell which
confirms the formation of the multicomponent nanoparticles.
F. 1. Schematic illustration of the major steps used for the production of Au/AgICSD, their functionalization with transferrin through the CALNN anchoring
groups, and with the surface preserve PEG moieties.
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F. 2. TEM images of (A) Au/AgICSD nanocomposites, (B) a magnified image of Au/AgICSD nanodimers, (C) STEM image of Au/AgICSD nanodimers,
(D) EDS data of Au/AgICSD nanodimers and, (E) UV-vis spectra of gold nanoparticles (blue line) and Au/AgICSD nanocomposites (black line).
Furthermore, TEM revealed that the AgI shell (with a
thickness of 5 nm) covers the internal Au core and mediated the
formation of the dimers. The composition of the Au/AgICSD
components was performed by ICP-MS analysis of Au, Ag,
and iodine [Fig. 2(D)]. The fractions of each metal component
in Au/AgICSD were 1001.2 ppm for Au, 184.9 ppm for
Ag, and 1433.9 ppm for iodine as revealed by ICP-MS.
Interestingly, optical properties of Au/AgICSD as shown in
Fig. 2(D) are attributed to the anisotropic and dimer-like shape
of Au/AgICSD nanocomposite. The absorption curves reveal
two peaks associated to the gold nanoparticles composition (at
532 and 760 nm), corresponding to the longitudinal plasmon
excitation at 530 nm and transversal plasmon excitation at
760 nm, respectively. In addition, one peak for the silver shell
appears at 420 nm and the iodine composition appears around
280 nm.
To confirm the core–shell structure observed in TEM, XPS
was performed on Au/AgICSD nanocomposites. Figure 3
shows the XPS narrow scan for Au 4 f , Ag 3d, I 3d, and
C1 of the Au/AgICSD (survey scan in the supplementary
material24). The presence of each element was determined
by its corresponding binding energy (BE).
F. 3. Binding energy profiles of Au 4 f , Ag 3d, I 3d, and C1 for the Au/AgICSD nanocomposites obtained from the XPS narrow scan, top left panel: Au 4 f
(5/2 and 7/2), top right panel: Ag 3d (5/2 and 7/2), bottom left: I 3d (5/2 and 7/2), bottom right: C1 scans.
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The Au-4 f , Ag-3d, and I-3d signals from XPS spectra of
Au/AgICSD revealed several spin orbit pairs. Their BE values
are assigned as follows: 83.8 and 87.7 eV for Au-4 f (7/2,
5/2), 367.8 and 374.0 eV for Ag-3d (7/2, 5/2), and 618.2.0
and 630.2 eV for I-3d (7/2, 5/2). The presence of two small
additional AgI peaks confirms the observation of the tridomain
nanodimer peaks that appear in the iodine scanning. These
two peaks are assigned at 621.0 and 632.0 eV, respectively.
Moreover, two components in the C-1s spectra were resolved
using the peak fitting, such as C—C bonds at 285.0 eV
and for C==O at 285.5 eV corresponding to the organic
molecules.
The stability and surface functions of Au/AgICSD were
obtained by coating with the PEG-b-AGE copolymer previ-
ously reported by our group.25 Since the surface coating
procedure needs to be performed in a nonaqueous inor-
ganic/organic solvent, a styrene linker was first applied to
the Au/AgICSD nanoparticles. Further, an exchange between
styrene coating molecules and PEG-b-AGE polymer was
performed by stirring them at room temperature for 24 h.
The resulted solution was dialyzed against water to obtain
PEG-b-AGE-Au/AgICSD nanodimers. The average thickness
of the polymer coating is approximately 2 nm and the final
Au/AgICSD nanodimer is about 37 nm with a polydispersity
index (PDI) of 0.254.
3.B. Conjugation of transferrin to Au/AgICSD
(Tf-Au/AgICSD)
The successful grafting of the Tf on the surface of the
nanodimers was first confirmed by XPS analysis (Fig. 4), in
which a new C==C sp3 covalent bond is formed while the
C—C sp2 from Tf and the C—N bond from both CALNN and
Tf disappear.
Z-potential measurement also confirms the transferrin
functionalization as demonstrated by the Z-potential value
changing from 23 mV for PEG-b-AGE coated Au/AgICSD
with –NH2 groups on the surface to −35 mV for Tf-
Au/AgICSD after the transferrin grafting (Fig. 4, bottom right
panel).
3.C. Target specific binding and cytotoxicity
of Tf-Au/AgICSD
3.C.1. Targeting capability
The targeting capability of developed Tf-Au/AgICSD
was tested in vitro using D556 medulloblastoma cells with
TfR over expression. Cells were incubated with both tar-
geted, Tf-Au/AgICSD conjugated with FITC labeled Tf
and nontargeted Au/AgICSD conjugated with FITC labeled
BSA (BSA-Au/AgICSD) as a control. Furthermore, we
also used a blocking experiment to confirm the binding
specificity of the targeted Tf-Au/AgICSD in which a fixed
amount of Tf was incubated with the cells to block the
transferrin receptors before adding the nanoparticles. Fluo-
rescence images in Figs. 5(A)–5(D) show that the green
fluorescence from FITC is stronger in cells treated with Tf-
Au/AgICSD [Fig. 5(B)] compared to the cells treated with
BSA-Au/AgICSD [Fig. 5(C)]. The blocking of transferrin
receptors reduced the cell uptake of targeted Tf-Au/AgICSD
[Fig. 5(D)]. These results indicate that the specific uptake
of the Tf-Au/AgICSD into the cancerous cells (that ex-
press high levels of TfR) is likely via a receptor-mediated
F. 4. Binding energy profiles of different samples obtained from C1 XPS narrow scans. Transferrin (top left panel), CALNN (top right panel), Tf-Au/AgICSD
nanodimer nanoparticles (bottom panel).
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F. 5. [(A)–(D)] Fluorescence images of the D556 medulloblastoma cells treated with different nanocomposites: control cells (A), cells treated with
Tf-Au/AgICSD (B), cells treated with BSA-Au/AgICSD (C), cells pretreated with a fix amount of Tf before adding the Tf-Au/AgICSD (D). Magnification
is 40×. Tf and BSA were labeled with FITC.
pathway. Furthermore, in order to demonstrate the uptake
of the Tf-AgI/-AuCSD into the cancer cells via receptor-
mediated internalization, fluorescence cell imaging was per-
formed with Tf-Au/AgICSD treated D556 medulloblastoma
cancer cells at different time points. The green florescence
images show a time dependent internalization of the FITC
labeled Tf-AgI/-AuCSD into the D556 cancerous cells after
30 min [Fig. 5(E) and 5(F)], 1 h [Figs. 5(G) and 5(H)], and 3
h [Figs. 5(I) and 5(J)] incubation. A weak green fluorescence
signal from cell internalized nanoparticles was observed in
the cells after 30 min of incubation with FITC labeled Tf-
Au/AgICSD.
In comparison, green fluorescence of FITC labeled Tf-
Au/AgICSD treated cells became much stronger after 3 h of
incubation. This observation is consistent with the early study
by Yang et al.26 which reported that the transferrin conjugated
gold nanoparticles were internalized by cells through the
endocytosis pathways shown in their atomic force microscopy
imaging.
3.C.2. Cytotoxicity evaluation
The toxicity of citrate coated AuNPs and AgI-AuCSD
as well as amphiphilic PEG-b-AGE polymer coated AuNPs
and AgI/AuCSD was evaluated at different concentrations
(range from 12.5 to 400 µg/ml) using MTT assay with
four types of cells: MDA231 breast cancer cells, human
embryonic kidney 293 cells, HeLa cells, and D556 medul-
loblastoma cells. The MTT experiments were done with 24
and 48 h, respectively. The results normalized to that of
Au nanoparticles (stabilized with citrate) are presented in
the supplementary material [1(A)–1(D)].27 All nanoparticles
tested presented some degrees of acute toxicity under the
conditions used in the study. However, the citrate-stabilized
AgI-AuCSD exhibited less cytotoxicity on the MDA 231
breast cancer cell line compared to other nanoparticles after
48 h of exposure. Moreover, coating the nanoparticles with
copolymer (PEG-b-AGE) improved the biocompatibility of
the nanomaterials [Figs. 6(A)–6(D)]. The synthesized PEG-b-
AGE coated Au/AgICSD did not show any significant toxicity
up to 50 µg/ml.
3.D. X-ray attenuation properties of Au/AgICSD
in CT imaging
The CT images corresponding to the contrast agent are
presented in Fig. 7(A), with their corresponding intensities
in Hounsfield units that were measured using the method
specified in Sec. 2.B.8. Compared with the clinically used
iodine agent, Omnipaque 350, both Au/AgICSD and AuNPs
showed enhanced contrast in CT, though, Au/AgICSD ex-
hibited significantly stronger contrast. The HU values of the
samples with different amounts of gold in nM were obtained
and presented in Fig. 7(A) such as for AuNPs: 0.5× 103
nM—4.2 HU [Fig. 7(a)]; 2.5×103 nM—11.7 HU [Fig. 7(b)];
12.6× 103 nM—62.3 HU [Fig. 7(c)]; 17.7× 103 nM—86.8
HU [Fig. 7(d)]; 25×103 nM—98.4 HU [Fig. 7(e)]; 50×103
nM—266 HU [Fig. 7(f)]; for AgI/AuCSD: 0.5× 103 nM—
79.8 HU [Fig. 7(h)]; 2.5× 103 nM—136.0 HU [Fig. 7(i)];
12.6×103 nM—230.1 HU [Fig. 7(j)]; 17.7×103 nM—376 HU
[Fig. 7(k)]; 25×103 nM—558.9 HU [Fig. 7(l)]; 50×103 nM
−1240.8 HU [Fig. 7(m)]; for clinically used Omnipaque 350
iodine contrast capability: 4.2×103 nM—134.4 HU [Fig. 7(g)]
and 9.7 × 103 nM—195.9 HU [Fig. 7(n)]. HU intensity
corresponding to the contrast agents increases proportionally
with the concentration [Fig. 7(B)].
The concentrations were determined by ICP-MS. It is found
that adding a AgI shell on Au/AgICSD generates substantially
stronger contrast than the AuNP core in CT images, suggesting
that the loading of iodine in the shell of gold nanoparticles is
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F. 6. [(A)–(D)] In vitro toxicity investigations of different concentrations of PEG-b-AGE and citrate coated AuNPs and Au/AgICSD (at different concentra-
tions 12.5–400 µg/ml) on D556 medulloblastoma cells, incubation time 24 and 48 h.
an efficient method to enhance the contrast without the need
of increasing the amount of gold.
3.E. Characterization of Au/AgICSD
in PA measurements
The results of photoacoustic measurements and the quan-
tification of the peak to peak value of both Au/AgICSD
and AuNP samples at different concentrations are shown in
Fig. 8. The photoacoustic signal from Au/AgICSD is much
higher than that from AuNPs at the same concentrations.
The concentrations leading to photoacoustic measurement of
SNR of 2 were 3 and 0.2 nM, respectively, for AuNPs and
Au/AgICSD. Therefore, the ratio between the molar extinction
coefficients of Au/AgICSD and AuNPs is about 15, again
suggesting that the loading of iodine in the shell of gold
nanoparticles may contribute to the increase of the optical
absorption contrast of the Au/AgICSD over pure AuNPs.
F. 7. X-ray CT images of solution phantoms of different materials. (A) Au/AgICSD and AuNPs (used as a control) prepared in a serial of dilutions along with
clinical iodine contrast agent Omnipaque 350 dilution. (B) The nanoparticulate diluted samples and their corresponding HU value.
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F. 8. (A) PA signals from Au/AgICSD and AuNPs samples at different concentrations calibrated based on the amount of Au in the samples. (B) PPV of
photoacoustic signals from Au/AgICSD and AuNPs samples corresponding to different concentrations.
4. DISCUSSION
We demonstrated that nanodimers of AgI/Au core–shell
nanocomposites can be prepared by using a novel seed
mediated approach, in which AuNPs are used as seeds for
the core and the composite shell of AgI then can be deposited
and assembled on the core spontaneously from solutions of
silver nitrate and potassium iodine. The layers of the AgI
shell of two core/shell particles then undergo fusion based on
the nonepitaxial shell growth, resulting in the formation of a
nanodimer. The formation and growth of the dimer structure is
likely due to the spontaneous chemisorption of iodine on the
surface of aspartic acid AuNPs. The rapid chemisorption of
iodine on gold was observed by Cheng et al.28 previously. They
demonstrated that the chemisorption of iodine takes place
on the citrate-stabilized gold nanoparticles in a controllable
manner, due to the electron donation between the KI and citrate
molecules, thus promoting the fusion of gold nanoparticles
together. The mechanism responsible for the formation of
Au/AgICSD dimer is believed to be similar to Ostwald
ripening (i.e., the small crystals of the sol solutions are
depositing on the surfaces of the seed particles), where the
KI addition enhances the rate of the Ostwald ripening process.
Moreover, Shipway et al. have reported that the interactions
between iodine and gold are very strong.29,30 Additionally,
XPS peak values for the binding energy (Fig. 3) are shifted
to the lower energy area compared with their corresponding
pure metals reported in the literature.31,32 This peak shifting
suggests the interaction of the shell with the Au core surface,
and it might be explained by a decreased electron density
on the interacting metal atoms or that the metal atoms are
in an oxidized state as they are coupling with the shell. This
decrease of the binding energy in the XPS spectra appears
to be inconsistent with some previous reports.33,34 Moreover,
the presence of two small additional AgI peaks confirms the
observation of the tridomain nanodimer peaks that appear in
the iodine scanning. These two peaks are assigned at 621.0
and 632.0 eV, respectively.
We showed that functionalization of the Au/AgICSD with
the cell targeting moiety transferrin can be accomplished
Au/AgICSD through a CALLN linker attached to PEG-b-AGE
polymer coated on the nanoparticle surface via the amide bond
formation between the NH2 groups of the polymer and COOH
group of CALNN linker. The successful functionalization was
demonstrated by an XPS analysis (Fig. 4) which revealed that
a new sp3 C—C covalent bond between CALNN linker and
Tf was formed while the sp2 C==C double bonds from Tf and
the C—N bond from both CALNN and Tf disappeared. This
reaction may take place due to the super-electrophilic ability
of CALLN that enables the formation of a transient bond with
the aromatic rings of Tf (phenylalanine or histidine), resulting
in the activation of the β-protons and the cleavage of the
C—N bond and ammonia dissipation. This reaction is likely
initiated by Friedel–Crafts attachment and is widely reported
in the literature.35 Furthermore, a decrease in the Z-potential of
Au/AgICSD suggests the anchoring of targeted Tf molecules
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on the surface of Au/AgICSD. The Z-potential changed
from 23 mV for PEG-b-AGE coated Au/AgICSD with –NH2
groups on the surface to −35 mV for Tf-Au/AgICSD after
grafting transferrin on the surface (Fig. 4, bottom right panel).
Furthermore, the developed PEG-b-AGE coated Au/AgICSD
has a good biocompatibility without significant cytotoxicity
up to a Au concentration of 50 µg/ml.
Our results on CT contrast enhancement showed that
Au/AgICSD are 4.3 times more efficient than the simple
AuNPs and 3 times more efficient than the clinically used
Omnipaque™ contrast agent. Even at low concentrations of
gold (0.5× 103 nM—79.8 HU), the Au/AgICSD generate
satisfactory contrast in CT images. Interestingly, the AgI shell
generated substantially stronger CT contrast than the AuNP
core, suggesting that the loading of iodine in the shell of gold
nanoparticles is a very effective and efficient way to increase
the contrast effect. Similarly, the photoacoustic signal from
Au/AgICSD was also much higher than that from AuNPs at the
same concentration. Additionally, the HU and PAT intensity
from Au/AgICSD were also much higher than those reported
in the early report10 even when concentration of Au/AgICSD
used in this study was 10 times lower. Therefore, the Au-AgI
core/shell structure may provide some form of synergistic
effect that enables further enhancement of both CT and PAI
contrast, although the phenomena of this synergistic effect
need to be further investigated in the future.
5. CONCLUSIONS
We report the development of a new class of core/
shell dimers (Au/AgICSD) as CT/PAI dual-modal biomarker
targeted contrast agents. The nanodimers are composed by
uniformly fusing gold, silver, and iodine to form core–shell
nanocomposite structure. TEM, STEM, XPS, and ICP-MS
were used to characterize the nanodimers and confirm the
core–shell formation with an overall size of 35 nm with a 15 nm
AuNP core covered by a AgI shell of 5 nm. The composition
ratio between these three components was determined to be
38% gold, 54.26% iodine, and 6.97% silver by ICP-MS.
The Au/AgICSD was stabilized in water by applying an
amphiphilic PEG-b-AGE polymer coating. Surface function-
alized with CALNN peptide linker allows for conjugating cell
targeting ligands, e.g., transferrin. The evaluation of CT and
PAI contrast enhancement demonstrated that prepared AgI/Au
CSD has dual-modality contrast-enhancing capability. The
Au/AgICSD is 4.3 times more efficient in CT enhancement
than the AuNPs without the shell and 3 times more efficient
than the clinically used Omnipaque™ 350 contrast agent. The
presence of the AgI shell around the AuNP core likely provides
additional contrast-enhancing effect in CT. Similarly, in PAT
imaging, the optical absorption contrast is further increased
with the Au/AgICSD nanodimer with the presence of the AgI
shell.
ACKNOWLEDGMENTS
This work is supported in parts by NIH No. R01CA154846-
02 (H.M. and L.Y.), NCI’s Cancer Nanotechnology Platform
Project (CNPP) grant (No. U01CA151810-02 to H.M. and
L.Y.), Emory Molecular Translational Imaging Center of
NCI’s in vivo Cellular and Molecular Imaging Center grant
(ICMIC, No. P50CA128301-01A10003 to H.M. and L.Y.),
and a grant from the Telemedicine and Advanced Technology
Research Center (TATRC) at the U.S. Army Medical Research
and Material Command (USAMRMC, No. W81XWH-12-1-
0138 to X.T.). The authors thank Dr. Jin Xie of Department
of Chemistry at University of Georgia for helping ICP-MS
measurement.
a)Authors to whom correspondence should be addressed. Electronic
addresses: hmao@emory.edu; Telephone: (404) 712-0357; Fax: (404) 712-
5689 and Xiangyang.Tang@emory.edu; Telephone: (404) 712-0357; Fax:
(404) 712-5689.
1C. P. Karger, P. Hipp, M. Henze, G. Echner, A. Hoss, L. Schad, and G. H.
Hartmann, “Stereotactic imaging for radiotherapy: Accuracy of CT, MRI,
PET and SPECT,” Phys. Med. Biol. 48(2), 211–221 (2003).
2V. Ntziachristos, “Going deeper than microscopy: The optical imaging
frontier in biology,” Nat. Methods 7(8), 603–614 (2010).
3D. J. Naczynski, M. C. Tan, R. E. Riman, and P. V. Moghe, “Rare earth
nanoprobes for functional biomolecular imaging and theranostics,” J. Mater.
Chem. B 2(20), 2958–2973 (2014).
4J. Kim, Y. Piao, and T. Hyeon, “Multifunctional nanostructured materials for
multimodal imaging, and simultaneous imaging and therapy,” Chem. Soc.
Rev. 38(2), 372–390 (2009).
5Y. Lin, H. Gao, D. Thayer, A. L. Luk, and G. Gulsen, “Photo-magnetic
imaging: Resolving optical contrast at MRI resolution,” Phys. Med. Biol.
58(11), 3551–3562 (2013).
6M. S. Judenhofer, H. F. Wehrl, D. F. Newport, C. Catana, S. B. Siegel, M.
Becker, A. Thielscher, M. Kneilling, M. P. Lichy, M. Eichner, K. Klingel,
G. Reischl, S. Widmaier, M. Rocken, R. E. Nutt, H. J. Machulla, K. Uludag,
S. R. Cherry, C. D. Claussen, and B. J. Pichler, “Simultaneous PET-MRI: A
new approach for functional and morphological imaging,” Nat. Med. 14(4),
459–465 (2008).
7M. P. Melancon, Y. Wang, X. Wen, J. A. Bankson, L. C. Stephens, S. Jasser,
J. G. Gelovani, J. N. Myers, and C. Li, “Development of a macromolecular
dual-modality MR-optical imaging for sentinel lymph node mapping,” In-
vest. Radiol. 42(8), 569–578 (2007).
8L. Sampath, S. Kwon, S. Ke, W. Wang, R. Schiff, M. E. Mawad, and E.
M. Sevick-Muraca, “Dual-labeled trastuzumab-based imaging agent for the
detection of human epidermal growth factor receptor 2 overexpression in
breast cancer,” J. Nucl. Med. 48(9), 1501–1510 (2007).
9J. Zhu, Y. Lu, Y. Li, J. Jiang, L. Cheng, Z. Liu, L. Guo, Y. Pan, and H. Gu,
“Synthesis of Au-Fe3O4 heterostructured nanoparticles for in vivo computed
tomography and magnetic resonance dual model imaging,” Nanoscale 6(1),
199–202 (2014).
10Y. Jin, Y. Li, X. Ma, Z. Zha, L. Shi, J. Tian, and Z. Dai, “Encapsulating
tantalum oxide into polypyrrole nanoparticles for x-ray CT/photoacoustic
bimodal imaging-guided photothermal ablation of cancer,” Biomaterials
35(22), 5795–5804 (2014).
11Y. Shao, S. R. Cherry, K. Farahani, K. Meadors, S. Siegel, R. W. Silverman,
and P. K. Marsden, “Simultaneous PET and MR imaging,” Phys. Med. Biol.
42(10), 1965–1970 (1997).
12Y. Seo, C. Mari, and B. H. Hasegawa, “Technological development and ad-
vances in single-photon emission computed tomography/computed tomog-
raphy,” Semin. Nucl. Med. 38(3), 177–198 (2008).
13E. Yang, W. Qian, Z. Cao, L. Wang, E. N. Bozeman, C. Ward, B. Yang,
P. Selvaraj, M. Lipowska, Y. A. Wang, H. Mao, and L. Yang, “Theranos-
tic nanoparticles carrying doxorubicin attenuate targeting ligand specific
antibody responses following systemic delivery,” Theranostics 5(1), 43–61
(2015).
14L. C. Gontard, A. Fernandez, R. E. Dunin-Borkowski, T. Kasama,
S. Lozano-Perez, and S. Lucas, “Transmission electron microscopy of
unstained hybrid Au nanoparticles capped with PPAA (plasma-poly-
allylamine): Structure and electron irradiation effects,” Micron 67, 1–9
(2014).
15W. Gao, W. Cao, H. Zhang, P. Li, K. Xu, and B. Tang, “Targeting lysosomal
membrane permeabilization to induce and image apoptosis in cancer cells
Medical Physics, Vol. 43, No. 1, January 2016
599 Orza et al.: Dual-modality contrast agent for CT and photoacoustic imaging 599
by multifunctional Au-ZnO hybrid nanoparticles,” Chem. Commun. (Cam-
bridge, U. K.) 50(60), 8117–8120 (2014).
16S. Zhang, M. Gong, D. Zhang, H. Yang, F. Gao, and L. Zou, “Thiol-PEG-
carboxyl-stabilized Fe2O3/Au nanoparticles targeted to CD105: Synthesis,
characterization and application in MR imaging of tumor angiogenesis,”
Eur. J. Radiol. 83(7), 1190–1198 (2014).
17J. Chen, Z. Guo, H. B. Wang, M. Gong, X. K. Kong, P. Xia, and Q. W.
Chen, “Multifunctional Fe3O4@C@Ag hybrid nanoparticles as dual modal
imaging probes and near-infrared light-responsive drug delivery platform,”
Biomaterials 34(2), 571–581 (2013).
18D. Gao, P. Zhang, C. Liu, C. Chen, G. Gao, Y. Wu, Z. Sheng, L. Song, and L.
Cai, “Compact chelator-free Ni-integrated CuS nanoparticles with tunable
near-infrared absorption and enhanced relaxivity for in vivo dual-modal
photoacoustic/MR imaging,” Nanoscale 7(42), 17631–17636 (2015).
19Z. Liu, T. Lammers, J. Ehling, S. Fokong, J. Bornemann, F. Kiessling, and
J. Gatjens, “Iron oxide nanoparticle-containing microbubble composites as
contrast agents for MR and ultrasound dual-modality imaging,” Biomate-
rials 32(26), 6155–6163 (2011).
20Z. Liu, F. Pu, J. Liu, L. Jiang, Q. Yuan, Z. Li, J. Ren, and X. Qu, “PEGylated
hybrid ytterbia nanoparticles as high-performance diagnostic probes for in
vivomagnetic resonance and x-ray computed tomography imaging with low
systemic toxicity,” Nanoscale 5(10), 4252–4261 (2013).
21L. Cheng, J. Liu, X. Gu, H. Gong, X. Shi, T. Liu, C. Wang, X. Wang, G.
Liu, H. Xing, W. Bu, B. Sun, and Z. Liu, “PEGylated WS2 nanosheets as a
multifunctional theranostic agent for in vivo dual-modal CT/photoacoustic
imaging guided photothermal therapy,” Adv. Mater. 26(12), 1886–1893
(2014).
22G. Tian, X. Zhang, X. Zheng, W. Yin, L. Ruan, X. Liu, L. Zhou, L. Yan, S. Li,
Z. Gu, and Y. Zhao, “Multifunctional Rbx WO3 nanorods for simultaneous
combined chemo-photothermal therapy and photoacoustic/CT imaging,”
Small 10(20), 4160–4170 (2014).
23X. Zheng, J. Shi, Y. Bu, G. Tian, X. Zhang, W. Yin, B. Gao, Z. Yang, Z.
Hu, X. Liu, L. Yan, Z. Gu, and Y. Zhao, “Silica-coated bismuth sulfide
nanorods as multimodal contrast agents for a non-invasive visualization of
the gastrointestinal tract,” Nanoscale 7(29), 12581–12591 (2015).
24See supplementary material at http://dx.doi.org/10.1118/1.4939062 for
more investigations of A-D in vitro toxicity on cell lines at different
concentrations of AuNPs and AgI/AuCSD.
25Y. Li, R. Lin, L. Wang, J. Huang, H. Wu, G. Cheng, Z. Zhou, T.
MacDonald, L. Yang, and H. Mao, “PEG-b-AGE polymer coated mag-
netic nanoparticle probes with facile functionalization and anti-fouling
properties for reducing non-specific uptake and improving biomarker
targeting,” J. Mater. Chem. B Mater. Biol. Med. 3(17), 3591–3603
(2015).
26P. H. Yang, X. Sun, J. F. Chiu, H. Sun, and Q. Y. He, “Transferrin-mediated
gold nanoparticle cellular uptake,” Bioconjugate Chem. 16(3), 494–506
(2005).
27C. Freese, C. Uboldi, M. I. Gibson, R. E. Unger, B. B. Weksler, I. A. Romero,
P.-O. Couraud, and C. J. Kirkpatrick, “Uptake and cytotoxicity of citrate-
coated gold nanospheres: Comparative studies on human endothelial and
epithelial cells,” Part. Fibre Toxicol. 9(23), 1–11 (2012).
28W. Cheng, S. Dong, and E. Wang, “Iodine-induced gold-nanoparticle
fusion/fragmentation/aggregation and iodine-linked nanostructured assem-
blies on a glass substrate,” Angew. Chem., Int. Ed. Engl. 42(4), 449–452
(2003).
29A. N. Shipway, E. Katz, and I. Willner, “Nanoparticle arrays on surfaces for
electronic, optical, and sensor applications,” ChemPhysChem 1(1), 18–52
(2000).
30A. N. Shipway, M. Lahav, R. Gabai, and I. Willner, “Investigations into
the electrostatically induced aggregation of Au nanoparticles,” Langmuir
16(23), 8789–8795 (2000).
31J. Leiro, E. Minni, and E. Suoninen, “Study of plasmon structure in
XPS spectra of silver and gold,” J. Phys. F: Met. Phys. 13(1), 215–221
(1983).
32S. K. Jo and J. M. White, “Characterization of adsorption states of atomic
iodine on Pt(111),” Surf. Sci. 261(1–3), 111–117 (1992).
33I. Fratoddi, I. Venditti, C. Battocchio, G. Polzonetti, C. Cametti, and M.
V. Russo, “Core shell hybrids based on noble metal nanoparticles and
conjugated polymers: Synthesis and characterization,” Nanoscale Res. Lett.
6(1), 98 (2011).
34M.-C. Bourg, A. Badia, and R. B. Lennox, “Gold–sulfur bonding in 2D and
3D self-assembled monolayers: XPS characterization,” J. Phys. Chem. B
104(28), 6562–6567 (2000).
35C. Paizs, A. Katona, and J. Retey, “The interaction of heteroaryl-acrylates
and alanines with phenylalanine ammonia-lyase from parsley,” Chem.–Eur.
J. 12(10), 2739–2744 (2006).
Medical Physics, Vol. 43, No. 1, January 2016
